# Neurology (movement disorders) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Muhammad Ali (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX001-SYN
- Date: 2026-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kwame Asante, MD
- Calendar frame: modern shifted

- Requested by: Celeste Moreau, MD

## Reason for consultation

Young-onset Parkinson's disease, diagnosed twelve years ago at 42, in a 54-year-old man whose slowness of movement now limits daily tasks on a modest levodopa dose. Please review the diagnosis, advise on the levodopa dose or another agent, and plan rehabilitation for his soft speech and gait. **S**

## History

Mr. Ali, a 54-year-old man with parkinsonism diagnosed twelve years ago at 42, is seen at the request of Dr. Moreau. Slowness of movement is his main limitation: buttoning, handwriting, and rising from low chairs take longer, most of all in the late morning and late afternoon. He has a mild right-hand tremor at rest. His voice is soft, and people have trouble hearing him in crowds. He takes carbidopa-levodopa 25/100 mg one tablet three times a day, often with meals, and notices no wearing-off before doses, no involuntary movements, no freezing, and no lightheadedness on standing. He has had no falls, hallucinations, dream enactment, or new urges to gamble, shop, or eat. He boxed professionally until three years before the diagnosis. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert, humorous, and engaged; reduced facial expression and blinking |
| Mental status | Fully oriented; fluent, coherent speech, soft and monotone |
| Eye movements | Full range, including vertical gaze; slightly slowed saccades; no square-wave jerks |
| Motor | MDS-UPDRS Part III 30 in the on state, about two hours after a dose. Bradykinesia with decrement on finger and foot tapping, worse on the right; rigidity in all limbs, worse on the right; mild right-hand rest tremor; no dyskinesia, dystonia, or myoclonus |
| Coordination and reflexes | No cerebellar signs; reflexes symmetric; plantar responses flexor |
| Gait | Short steps with reduced arm swing; no freezing; recovers after three steps on the pull test; Hoehn and Yahr stage 2.5 |
| Orthostatic check | 128/80 mmHg supine and 122/78 mmHg at 3 minutes standing, without symptoms |

BP 126/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 102 kg; BMI 28 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Moreau's first-visit assessment four weeks ago: MDS-UPDRS Part III 30, Hoehn and Yahr stage 2.5, Timed Up and Go 13 seconds, pull test, supine and standing blood pressure, MoCA 27, PHQ-9 3, EAT-10 2, sleep and impulse-control screens; blood count, chemistry, vitamin B12, and TSH from the same visit; and today's supine and standing blood pressure. 

## Assessment

1. **Parkinson's disease, young onset, Hoehn and Yahr stage 2.5** (G20.A1). Clinically established Parkinson's disease by the MDS criteria: bradykinesia with rest tremor and rigidity, a clear and lasting response to levodopa, and no red flags or absolute exclusions. There is no early falling, no vertical gaze palsy, no cerebellar or pyramidal sign, no early autonomic failure, and no early dementia. Whether repeated blows to the head in his boxing career contributed cannot be confirmed or excluded during life. The course and examination are those of Parkinson's disease, and the question does not change his treatment. **S**
2. **Bradykinesia on a modest levodopa dose**. Bradykinesia limits daily tasks on levodopa 100 mg three times daily, with no motor complications. Taking doses with meals blunts absorption. Raising levodopa is the simplest and best-tolerated step. A dopamine agonist would add risks of sleepiness, impulse-control disorders, and hallucinations, and an MAO-B inhibitor would add only a small benefit. **S**
3. **Hypokinetic dysarthria with soft speech** (R47.1). Soft, monotone speech typical of Parkinson's disease, which responds well to intensive voice treatment. **S**
4. **Gait, balance, and fall risk**. No falls, but short steps and a three-step pull-test recovery show early postural instability. Supervised exercise and balance training lower fall risk and improve gait. **S**
5. **Genetic testing**. Genetic testing with counseling is now offered to everyone with Parkinson's disease, and young onset makes it more informative. The result would not change his current treatment. **S**

## Recommendations

1. Increase carbidopa-levodopa to one and a half 25/100 mg tablets (levodopa 150 mg) three times daily, taken 30 minutes before meals, and spread protein through the day.
2. Check supine and three-minute standing blood pressure at the next visit after the increase; report lightheadedness, involuntary movements, nausea, or sleepiness.
3. No dopamine agonist or MAO-B inhibitor for now; review if motor fluctuations appear.
4. Avoid dopamine-blocking drugs (metoclopramide, prochlorperazine, and antipsychotics other than quetiapine, clozapine, or pimavanserin); use ondansetron if an antiemetic is needed.
5. Four-week intensive speech therapy course (LSVT LOUD), then daily voice practice.
6. Physical therapy for gait and balance, building to at least 150 minutes a week of aerobic, strength, and balance exercise.
7. No brain imaging or laboratory workup is needed, because there are no atypical features.
8. Genetic testing with counseling offered today; he will decide at the yearly review.
9. Primary care follows him every three months on the CMID schedule, with motor examination, Hoehn and Yahr stage, fall check, orthostatic blood pressure, and psychosis and impulse-control questions at each visit, and cognition, mood, sleep, autonomic, swallowing, and speech screens yearly.

## Strengths and supports

- Supports: spouse, adult children, and long-time friends and staff who travel with him **S**

## Communication

Discussed with Dr. Moreau, who sees him the same day. The plan was explained to Mr. Ali, who agreed to it. **S**

## Follow-up

Movement disorders review in one year, or sooner for motor fluctuations, dyskinesia, falls, hallucinations, or a cognitive change. **S**

## Guideline basis

- Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021), American Academy of Neurology (Neurology)
- MDS clinical diagnostic criteria for Parkinson's disease (2015), International Parkinson and Movement Disorder Society (Movement Disorders)
- The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017), American Autonomic Society and National Parkinson Foundation (Journal of Neurology)
- CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026), Aether Forge
